Remdesivir More Effective than Placebo for Time to COVID-19 Recovery
For adults hospitalized with COVID-19 with lower respiratory tract infection, time to recovery is shorter with remdesivir than placebo.
For adults hospitalized with COVID-19 with lower respiratory tract infection, time to recovery is shorter with remdesivir than placebo.
Treatment with interferon beta-1b in combination with lopinavir/ritonavir and ribavirin was found to be safe and superior to lopinavir/ritonavir alone for reducing the duration of viral shedding and hospital stay in adults with COVID-19.
The Food and Drug Administration (FDA) is alerting healthcare professionals and consumers of a voluntary recall of 3 lots of Amneal’s Nizatidine Oral Solution (15mg/mL) due to potential contamination with N-Nitrosodimethylamine (NDMA), a probable human carcinogen.
A number of institutions this week announced their participation in an international clinical drug trial evaluating the safety and efficacy of remdesivir in hospitalized patients with COVID-19.
One in 10 older adults hospitalized for common medical conditions are discharged with intensified diabetes medications, despite the fact that nearly half are unlikely to benefit from the intensification.
The most clinically appropriate mode of hydrocortisone administration during major stress in patients with adrenal insufficiency is continuous intravenous hydrocortisone.
Certain types of EpiPens and their generic counterparts may fail or delay injection of lifesaving epinephrine for severe allergic reactions.
So-called “Pharma Bro” Martin Shkreli faces charges of price fixing of a drug used to treat the potentially fatal condition toxoplasmosis.
Since patients with chronic diseases are often prescribed opioids, researchers sought to examine the association between opioid-related hospitalization and patients with chronic disease. Since patients with chronic diseases are often prescribed opioids, researchers sought to examine the association between opioid-related hospitalization and patients with chronic disease.
The US approval and regulation processes for pharmaceutical agents have evolved during the last four decades, according to a study published in the Journal of the American Medical Association.